Grzegorz S. Nowakowski, MD

Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center

Articles

Dr Nowakowski on the FDA Approval of Brentuximab Vedotin for R/R LBCL

March 13th 2025

Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in relapsed/refractory LBCL.

Other Key Follicular Lymphoma Data From ASH 2024

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024.

Data for Mosunetuzumab in Newly Diagnosed Follicular Lymphoma

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.

2-Year Follow-Up Data for Liso-Cel in R/R Follicular Lymphoma

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.

CD19 Expression Loss and Tafasitamab in R/R DLBCL

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.

Clinical Experience Using Tafasitamab Plus Lenalidomide in DLBCL

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss their clinical practice experience using tafasitamab in relapsed/refractory DLBCL.

The Phase 3 inMIND Trial: Tafasitamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

February 4th 2025

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for tafasitamab in relapsed/refractory follicular lymphoma.

Dissecting the Current Treatment Landscape for R/R Follicular Lymphoma

December 20th 2024

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.

Dr Nowakowski on the Significance of the TakeAim Lymphoma Trial in PCNSL

October 17th 2024

Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.

Dr Nowakowski on the Implications of the FDA Approval of Epcoritamab in Follicular Lymphoma

October 17th 2024

Grzegorz S. Nowakowski, MD, discusses the clinical implications of the FDA approval of third-line epcoritamab for relapsed/refractory follicular lymphoma.

Dr Nowakowski on Unmet Needs to be Addressed in R/R Follicular Lymphoma

September 13th 2024

Grzegorz S. Nowakowski, MD, discusses unmet needs that remain to be addressed in patients with relapsed/refractory follicular lymphoma.

Dr Nowakowski on the Current Treatment Landscape for DLBCL

September 6th 2024

Grzegorz S. Nowakowski, MD, discusses the treatment landscape for DLBCL and the need for novel therapeutic approaches in the second-line setting.

Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular Lymphoma

September 4th 2024

Grzegorz S. Nowakowski, MD, discusses results from the EPCORE NHL-1 trial of third-line epcoritamab in relapsed/refractory follicular lymphoma.

Dr Nowakowski on the FDA Approval of Epcoritamab in R/R Follicular Lymphoma

July 17th 2024

Grzegorz S. Nowakowski, MD, discusses the significance of the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.

Future Directions and Unmet Needs in Relapsed/Refractory MCL

February 20th 2024

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Sequencing Therapies in the Third-Line and Beyond Setting for MCL

February 13th 2024

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

Current Treatment Options in Third-line MCL

February 13th 2024

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

Current Treatment Options in Second-line MCL

February 6th 2024

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

ASH 2023 Updates on Frontline Therapies in MCL

February 6th 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Current Treatment Options in First-Line MCL

January 30th 2024

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.